X. Wang
6 Papers
4 Citations
X. Wang is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 6 publications.
Chat about Author
Papers
Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies
J Li,Y. Cheng,C. Bai,J Xu,Lin Shen,J. Li,Z. Li,Yihebali Chi,E. Li,N. Xu,T. Liu,Wenhui Lou,Y. Bai,XY Yuan,X. Wang,Y. Yuan,J. Chen,Shaoxing Guan,Songhua Fan,W. Su +19 more
TL;DR: In this article , the authors evaluated the association between treatment-related adverse events (TRAEs) and efficacy outcomes of surufatinib in patients with advanced neuroendocrine tumors.
5
Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395].
Shengxiang Ren,J. Wang,Jianming Yang,Tetsuya Mitsudomi,D.H. Lee,Z. Wang,Qian Chu,Philip C. Mack,Y. Cheng,Jipeng Duan,Y. Fan,Baohui Han,Zhouguang Hui,A Liu,J. Liu,Y. Lu,Z. Ma,M. Shi,Yongqian Shu,Q. Q. Song,X. Song,C. Wang,X. Wang,Z. Wang,Y. Xu,L. Zhang,M. Zhao,B. Zhu,J. Zhang,C. Zhu,Fred R. Hirsch +30 more
TL;DR: Ying et al. as discussed by the authors proposed a consensus for HER2 alterations testing in non-small-cell lung cancer and found that such alterations are, in general, considered markers of poor prognosis.
2
Kiaa1429 regulates hippo‐yap pathway to maintain the tumorigenicity of diffuse large b‐cell lymphoma via an m6a‐dependent manner
TL;DR: In this article , an epitranscriptomic mechanism mediated by the m6A methyltransferase KIAA1429 in diffuse large B-cell lymphoma (DLBCL) was unraveled.
Targeted agents combined with chop compared with chop as the first‐line therapy for peripheral t‐cell lymphoma: preliminary results from a phase 2 guidance‐03 trial
Ming-ci Cai,Shu Cheng,Hongmei Jing,Gongzhen Cui,T. Niu,X. Wang,J. Shen,L F Huang,Yu Huang,Li Wang,Pengpeng Xu +10 more
TL;DR: A phase 2, multi-center, non-randomized clinical trial, comparing the efficacy and safety of targeted agents combined with CHOP (CHOPX) in newly diagnosed patients with peripheral T-cell lymphoma (PTCL) was conducted in this article .
[TFE3 positive and pigment rich perivascular epithelioid cell tumor of stomach: report of a case].
X.T. Sun,Shujing Du,H. G. Ma,J.-M. Li,X. Wang +4 more
- 08 Jan 2022
TL;DR: In this article , the authors describe PECOMA as "a company that provides services to the general public" and "providers" such as: "http://www.pecoma.com".